Rheumatoid Arthritis Clinical Trials

Showing 14061-14080 of 47,334 trials

First in Human Study of TLC-ART 101 (ACTU 2001)

NCT05850728

This study is a prospective, open-label, single-site, first-in-human study of a long-acting, injectable combination antiretroviral therapy platform, with a pharmacologically-guided adaptive design for dose escalation, de-escalation, and study duration. The study is designed to learn whether the formulation can be used as a platform for other drugs for treatment of HIV. The formulation is a drug combination nanoparticle (DCNP). The study will be conducted by UW Positive Research. The sample size for this study is 12-16. The study population consists of healthy adults without HIV. The study duration is 57 days per participant at the start of the study.

Human Immunodeficiency VirusTreatmentAntiretroviral Therapy

University of Washington12 participantsStarted Apr 2023

Seattle, Washington, United States

COMPLETEDPhase 2

Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

NCT03233204

This phase II Pediatric MATCH trial studies how well olaparib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with defects in deoxyribonucleic acid (DNA) damage repair genes that have spread to other places in the body (advanced) and have come back (relapsed) or do not respond to treatment (refractory). Olaparib is an inhibitor of PARP, an enzyme that helps repair DNA when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy.

Advanced Malignant Solid NeoplasmAnn Arbor Stage III Childhood Non-Hodgkin LymphomaAnn Arbor Stage IV Childhood Non-Hodgkin Lymphoma+33 more

National Cancer Institute (NCI)6 participantsStarted Sep 2017

Birmingham, Alabama, United States • Anchorage, Alaska, United States • Mesa, Arizona, United States +110 more locations

First in Human Study of TLC-ART 101 (ACTU 2001)

Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

Related Searches

Evaluation of Nevisense as Support Tool for the Diagnose of Keratinocyte Skin Cancer

Association Between Perioperative Blood and Interstitial Fluid Glucose Level and Clinically Relevant Postoperative Pancreatic Fistula in Different Pancreatic Surgeries

Remote Monitoring of Patients With an Inflammatory Bowel Disease Under no or Maintenance Therapy

EMI Therapy for Depression in Hong Kong

Brief Motivational Intervention (BMI) on the Deprescription of Benzodiazepines and Related Substances in Adult Chronic Drug Users

Rhomboid Intercostal Block with Subserratus Plane Block in Bariatric Surgery

The Real-world Study of Rimegepant Treatment in Female Migraine Patients of China

Virtual Reality With Mirror Therapy on Upper Limb Function

Evaluation of the Efficacy and Safety of Furmonertinib Combined with Bevacizumab As First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer with Brain Metastases: a Single-Arm, Open-Label, Prospective Phase II Clinical Study

Evaluation of Horizontal Anterior Mandibular Augmentation With Split Bone Block Technique From the Chin

Metabolism in the Human Brain Following Consumption of a Keto-ester in Alcohol Use Disorder (AUD) With Proton Magnetic Resonance Spectroscopic Imaging (MRSI)

Analysis of Spatiotemporal Gait Parameters in Patients With Megaprosthesis.

Study to Determine the Safety and Tolerability of TG-C in Subjects with Back Pain Due to Degenerative Disc Disease

Reduction of Microemboli of Air Using a New Developed Air Trap (EmbolessTM) During Haemodialysis

Evaluation of Phacogoniotomy in Medically-controlled POAG

A Phase III Trial of e-TNS for the Acute Treatment of Migraine

Prospective Evaluation of Biliary Tissue Sampling with ERCP

Pegasys® in Patients With Myeloproliferative Diseases